Specifically, it was demonstrated the clinically used TRAIL-R2-specific antibody AMG655 and recombinant, non-tagged TRAIL (e.g., Dulanermin), both of which show only little activity in killing cancer cells in monotherapy, when combined they synergized in the killing of cancer cell lines derived from a variety of cancer entities including ovarian and lung cancer [11, 37]. This evidence concerns the gene TNFRSF10B and cancer.